There are currently 170 active clinical trials seeking participants for Acute Myeloid Leukemia research studies. The states with the highest number of trials for Acute Myeloid Leukemia participants are California, Illinois, New York and Texas.
Venetoclax and Lintuzumab-Ac225 in AML Patients
NCT03867682
Recruiting
The study is a multicenter, open label Phase I/II trial. 1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive relapsed/refractory AML. (Phase 1 portion) 2. To assess the percentage of patients with CR, CRh, or Overall Response (CR + CRh), up to 6 months after the start of treatment without receiving other AML therapies. (Phase 2 portion)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/02/2023
Locations: University of California, Los Angeles, California +4 locations
Conditions: Acute Myeloid Leukemia, Relapsed Adult AML
Register for Updates
Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02
NCT04167696
Recruiting
An open-label, phase I, multi-center study to determine in relapsed/refractory (r/r) acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) patients the recommended dose of CYAD-02 after a non-myeloablative preconditioning chemotherapy followed by a potential CYAD-02 consolidation cycle for non-progressive patient. A maximum of 27 r/r AML/MDS patients will be evaluated in this study in case of no dose limiting toxicity (DLT) and no replacement of patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/08/2020
Locations: Mayo Clinic Cancer Center, Jacksonville, Florida +4 locations
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
Register for Updates